ClinicalTrials.gg
CompletedNCT00624052Updated May 20, 2014Results posted

26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension

A Phase 3 interventional study of fixed-dose combination of telmisartan 40mg+amlodipine 10mg and fixed-dose combination of telmisartan 80mg+amlodipine10mg in Hypertension, sponsored by Boehringer Ingelheim. Completed at 92 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-20.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
838
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
19th of 74
838 · median 381
Started
2008
with 3 others
Phase 3
43 of 122
1 open now
Registered
36th of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 19th largest by enrollment of the 74 interventional ones that give a count, is one of 4 that started in 2008, is one of 43 in phase 3, and was the 36th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg (T80/A10) during open-label treatment for at least six months.

An additional objective is to assess the efficacy and safety of concomitant administration of either T40/A10 or T80/A10 with any other therapies commonly used in the treatment of hypertension.

The primary endpoint is the proportion of patients achieving DBP control (defined as mean seated DBP \< 90 mmHg at trough i.e. approximately 24 hours after last dose of study treatment) at six months of treatment or at last trough observation during the treatment period (i.e. last trough observation carried forward).

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of essential hypertension

Exclusion criteria

Exclusion Criteria:

  • pregnancy, breast-feeding, unwilling to use effective (if female of ).
  • development of any condition in the preceding trial that could be worsened by telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg (T80/A10).
  • discontinuation from the preceding trial.
  • known or suspected secondary hypertension.
  • mean seated systolic blood pressure (SBP) >= 180 mmHg and/or mean seated diastolic blood pressure (DBP) >= 120 mmHg at any visit.
  • any hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.
  • clinically relevant hyperkalaemia.
  • uncorrected volume or sodium depletion.
  • primary aldosteronism.
  • hereditary fructose or lactose intolerance.
  • symptomatic congestive heart failure.
  • patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).
  • any new drug or alcohol dependency since signing consent of the preceding trial.
  • concurrent participation in another clinical trial or any therapy since completing the preceding trial.
  • hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.
  • known allergic to any component of the formulations under investigation. [Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine calcium channel blockers (CCBs).] non-compliance with study medication (defined as \<80% or >120%) during the preceding trial.
  • administration of ARBs or dihydropyridine CCBs (apart from trial medication). any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
838 participants (actual)

Interventions

  • Drugfixed-dose combination of telmisartan 40mg+amlodipine 10mg
  • Drugfixed-dose combination of telmisartan 80mg+amlodipine10mg
06

What researchers measure

Primary outcomes

  1. Trough Seated Diastolic Blood Pressure (DBP) Control

    The number of patients who reached the target DBP of \<90mmHg

    Time frame: End of study (34 weeks or last value on treatment)

Secondary outcomes

  1. Trough Seated Systolic Blood Pressure (SBP) Control

    The number of patients who reached the target SBP of \>=140mmHg

    Time frame: End of study (34 weeks or last value on treatment)

  2. Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure

    Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.6

    Time frame: Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment

  3. Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052

    The difference between the last available troughs represents the additional reduction in DBP in this study

    Time frame: Last available trough in NCT00553267 to end of study (34 weeks or last value on treatment)

  4. Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure

    Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.6

    Time frame: Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment

  5. Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052

    The difference between the last available troughs represents the additional reduction in SBP in this study

    Time frame: Last available trough in NCT00624052 to end of study (34 weeks or last value on treatment)

  6. Trough Seated DBP Response

    The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg

    Time frame: End of study (34 weeks or last value on treatment)

  7. Trough Seated SBP Response

    The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg

    Time frame: End of study (34 weeks or last value on treatment)

  8. Trough BP Normality Classes

    The number of patients who reach predefined BP categories

    Time frame: End of study (34 weeks or last value on treatment)

  9. Time to First Additional Antihypertensive

    Time from first intake of medication to first intake of an antihypertensive other than the study drug

    Time frame: up to 34 weeks

  10. Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control

    The number of patients with DBP control (DBP\>=90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment

    Time frame: up to 34 weeks

  11. Additional Reduction in DBP by Use of Additional Antihypertensive Therapy

    Difference in trough DBP from last visit before add-on therapy and last visit during NCT00624052

    Time frame: up to 34 weeks

  12. Additional Reduction in SBP by Use of Additional Antihypertensive Therapy

    Difference in trough SBP from last visit before add-on therapy and last visit during NCT00624052

    Time frame: up to 34 weeks

  13. Trough DBP Control Pre- and Post- Uptitration

    The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before uptitration to telmisartan 80mg and amlodipine 10mg compared to first trough DBP taken after uptitration. Uptitration could be based DBP\>90 or investigator opinion.

    Time frame: up to 34 weeks

07

Results

Posted Mar 25, 2010

Participant flow

Participant flow — Overall Study
MilestoneTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Started2194369192
Completed2044228888
Not completed151434
Withdrew: Adverse event7603
Withdrew: Lack of efficacy1100
Withdrew: Lost to follow-up2310
Withdrew: Non compliant with the protocol2111
Withdrew: Consent withdrawn3110
Withdrew: Changed job/ran out if meds0200

Outcome measures

PrimaryTrough Seated Diastolic Blood Pressure (DBP) Control

The number of patients who reached the target DBP of \<90mmHg

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated Diastolic Blood Pressure (DBP) Control
patientsTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Yes (DBP<90 mmHg)2014027270
No (DBP>=90 mmHg)15341922
Statistical analysis
  • Telmisartan 40mg and Amlodipine 10mg vs Randomised Telmisartan 80mg and Amlodipine 10mg · Cochran-Mantel-Haenszel · Odds ratio (or): 0.88 · 95% CI 0.47 to 1.66
  • Telmisartan 40mg and Amlodipine 10mg vs Titrated Telmisartan 80mg and Amlodipine 10mg · Cochran-Mantel-Haenszel · Odds ratio (or): 0.28 · 95% CI 0.14 to 0.59
  • Telmisartan 40mg and Amlodipine 10mg vs Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on · Cochran-Mantel-Haenszel · Odds ratio (or): 0.24 · 95% CI 0.12 to 0.48
  • Randomised Telmisartan 80mg and Amlodipine 10mg vs Titrated Telmisartan 80mg and Amlodipine 10mg · Cochran-Mantel-Haenszel · Odds ratio (or): 0.32 · 95% CI 0.17 to 0.59
  • Randomised Telmisartan 80mg and Amlodipine 10mg vs Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on · Cochran-Mantel-Haenszel · Odds ratio (or): 0.27 · 95% CI 0.15 to 0.49
  • Titrated Telmisartan 80mg and Amlodipine 10mg vs Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on · Cochran-Mantel-Haenszel · Odds ratio (or): 0.84 · 95% CI 0.42 to 1.68
SecondaryTrough Seated Systolic Blood Pressure (SBP) Control

The number of patients who reached the target SBP of \>=140mmHg

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated Systolic Blood Pressure (SBP) Control
patientsTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Yes (SBP<140 mmHg)1793667051
No (SBP>=140 mmHg)37702141
SecondaryChange From Baseline to End of Study in Trough Seated Diastolic Blood Pressure

Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.6

Time frame:
Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment
Reported as:
Least squares mean · mmHg
Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure
mmHgTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure-13.41 ± 0.44-13.36 ± 0.31-11.52 ± 0.69-10.64 ± 0.67
SecondaryChange in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052

The difference between the last available troughs represents the additional reduction in DBP in this study

Time frame:
Last available trough in NCT00553267 to end of study (34 weeks or last value on treatment)
Reported as:
Least squares mean · mmHg
Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052
mmHgTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052-4.36 ± 0.48-4.97 ± 0.34-5.51 ± 0.74-5.43 ± 0.73
SecondaryChange From Baseline to End of Study in Trough Seated Systolic Blood Pressure

Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.6

Time frame:
Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment
Reported as:
Least squares mean · mmHg
Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure
mmHgTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure-14.76 ± 0.72-15.93 ± 0.5-14.85 ± 1.12-12.44 ± 1.1
SecondaryChange in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052

The difference between the last available troughs represents the additional reduction in SBP in this study

Time frame:
Last available trough in NCT00624052 to end of study (34 weeks or last value on treatment)
Reported as:
Least squares mean · mmHg
Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052
mmHgTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052-4.73 ± 0.73-6.02 ± 0.51-6.55 ± 1.11-5.61 ± 1.1
SecondaryTrough Seated DBP Response

The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated DBP Response
patientsTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Yes (Responder)2014057173
No (Non-responder)13291618
SecondaryTrough Seated SBP Response

The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated SBP Response
patientsTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Yes (Responder)1904017569
No (Non-responder)24331222
SecondaryTrough BP Normality Classes

The number of patients who reach predefined BP categories

Time frame:
End of study (34 weeks or last value on treatment)
Reported as:
Number · patients
Trough BP Normality Classes
patientsTelmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-on
Optimal (SBP<120 and DBP<80 mmHg)122053
Normal (SBP<130 and DBP<85 mmHg and not optimal)701461413
High-normal (SBP<140 DBP<90 mmHg and not normal)941894629
Stage 1 hypertension (SBP<160 and DBP<100 mmHg32762343
Stage 2 hypertension (SBP>=160 and DBP>=100 mmHg)8534
SecondaryTime to First Additional Antihypertensive

Time from first intake of medication to first intake of an antihypertensive other than the study drug

Time frame:
up to 34 weeks
Reported as:
Mean · Days
Time to First Additional Antihypertensive
DaysTelmisartan 40mg and Amlodipine 10mg
Time to First Additional Antihypertensive91.9 ± 45.2
SecondaryNumber of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control

The number of patients with DBP control (DBP\>=90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment

Time frame:
up to 34 weeks
Reported as:
Number · patients
Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control
patientsPre-antihypertensive: Yes (DBP<90 mmHg)Pre-antihypertensive: No (DBP>=90 mmHg)Pre-antihypertensive: Total
Post-antihypertensive: Yes (DBP<90 mmHg)276794
Post-antihypertensive: No (DBP>=90 mmHg)42327
Post-antihypertensive: Total3190121
SecondaryAdditional Reduction in DBP by Use of Additional Antihypertensive Therapy

Difference in trough DBP from last visit before add-on therapy and last visit during NCT00624052

Time frame:
up to 34 weeks
Reported as:
Mean · mmHg
Additional Reduction in DBP by Use of Additional Antihypertensive Therapy
mmHgTelmisartan 40mg and Amlodipine 10mg
Additional Reduction in DBP by Use of Additional Antihypertensive Therapy-6.79 ± 7.39
SecondaryAdditional Reduction in SBP by Use of Additional Antihypertensive Therapy

Difference in trough SBP from last visit before add-on therapy and last visit during NCT00624052

Time frame:
up to 34 weeks
Reported as:
Mean · mmHg
Additional Reduction in SBP by Use of Additional Antihypertensive Therapy
mmHgTelmisartan 40mg and Amlodipine 10mg
Additional Reduction in SBP by Use of Additional Antihypertensive Therapy-7.79 ± 12.37
SecondaryTrough DBP Control Pre- and Post- Uptitration

The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before uptitration to telmisartan 80mg and amlodipine 10mg compared to first trough DBP taken after uptitration. Uptitration could be based DBP\>90 or investigator opinion.

Time frame:
up to 34 weeks
Reported as:
Number · patients
Trough DBP Control Pre- and Post- Uptitration
patientsPre-titration: Yes (DBP<90 mmHg)Pre-titration: No (DBP>=90 mmHg)Pre-titration: Total
Post-titration: Yes (DBP<90 mmHg)306168474
Post-titration: No (DBP>=90 mmHg)1890108
Post-titration: Total324258582

Adverse events

Collected over From day of first dose through to the day after last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telmisartan 40mg and Amlodipine 10mg—4/838 (0.5%)0/838 (0%)
Telmisartan 80mg and Amlodipine 10mg—13/611 (2.1%)0/611 (0%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventTelmisartan 40mg and Amlodipine 10mgTelmisartan 80mg and Amlodipine 10mg
Hypertensive crisisVascular disorders0/8382/611
Atrial fibrillationCardiac disorders1/8381/611
Cardiac failure chronicCardiac disorders0/8381/611
Myocardial ischaemiaCardiac disorders0/8381/611
Chest painGeneral disorders0/8381/611
CholecystitisHepatobiliary disorders0/8381/611
Pulmonary tuberculosisInfections and infestations0/8381/611
Stent related infectionInfections and infestations0/8381/611
Ankle fractureInjury, poisoning and procedural complications0/8381/611
FallInjury, poisoning and procedural complications0/8381/611

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Telmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-onTotal
Mean56.2 ± 9.957.3 ± 9.455.2 ± 9.753.3 ± 10.356.4 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Telmisartan 40mg and Amlodipine 10mgRandomised Telmisartan 80mg and Amlodipine 10mgTitrated Telmisartan 80mg and Amlodipine 10mgTelmisartan 40mg or 80mg and Amlodipine 10mg + add-onTotal
Female932063137367
Male1262306055471
08

Study locations

92 sites
  • 1235.8.61003 Boehringer Ingelheim Investigational Site
    Gosford, New South Wales, Australia
  • 1235.8.61004 Boehringer Ingelheim Investigational Site
    Liverpool, New South Wales, Australia
  • 1235.8.61002 Boehringer Ingelheim Investigational Site
    Kippa-Ring, Queensland, Australia
  • 1235.8.61001 Boehringer Ingelheim Investigational Site
    Milton, Queensland, Australia
  • 1235.8.61005 Boehringer Ingelheim Investigational Site
    Elizabeth Vale, South Australia, Australia
  • 1235.8.43007 Boehringer Ingelheim Investigational Site
    Eggenburg, Austria
  • 1235.8.43006 Boehringer Ingelheim Investigational Site
    Hainburg a.d. Donau, Austria
  • 1235.8.43001 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1235.8.43002 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1235.8.43003 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1235.8.35912 Boehringer Ingelheim Investigational Site
    Bourgas, Bulgaria
  • 1235.8.35902 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.8.35903 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.8.35904 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.8.35905 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.8.35906 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.8.35907 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.8.35910 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.8.35911 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.8.42002 Boehringer Ingelheim Investigational Site
    Benatky nad Jizerou, Czech Republic
  • 1235.8.42006 Boehringer Ingelheim Investigational Site
    Brno, Czech Republic
  • 1235.8.42001 Boehringer Ingelheim Investigational Site
    Plzen, Czech Republic
  • 1235.8.42003 Boehringer Ingelheim Investigational Site
    Praha 5, Czech Republic
  • 1235.8.42004 Boehringer Ingelheim Investigational Site
    Pribram, Czech Republic
  • 1235.8.42005 Boehringer Ingelheim Investigational Site
    Slany, Czech Republic
  • 1235.8.42007 Boehringer Ingelheim Investigational Site
    Strakonice, Czech Republic
  • 1235.8.35304 Boehringer Ingelheim Investigational Site
    Birr, Ireland
  • 1235.8.35305 Boehringer Ingelheim Investigational Site
    Carrigtowhill, Ireland
  • 1235.8.35303 Boehringer Ingelheim Investigational Site
    Gorey, Co. Wexford, Ireland
  • 1235.8.35306 Boehringer Ingelheim Investigational Site
    Mallow, Ireland
  • 1235.8.35301 Boehringer Ingelheim Investigational Site
    New Ross, Ireland
  • 1235.8.39002 Boehringer Ingelheim Investigational Site
    Broni (pv), Italy
  • 1235.8.39006 Boehringer Ingelheim Investigational Site
    Coppito (AQ), Italy
  • 1235.8.39001 Boehringer Ingelheim Investigational Site
    Ferrara, Italy
  • 1235.8.64003 Boehringer Ingelheim Investigational Site
    Dunedin, New Zealand
  • 1235.8.64002 Boehringer Ingelheim Investigational Site
    Otahuhu, Auckland, New Zealand
  • 1235.8.64001 Boehringer Ingelheim Investigational Site
    Tauranga, New Zealand
  • 1235.8.70004 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 1235.8.70005 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 1235.8.70006 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 1235.8.70007 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 1235.8.70008 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 1235.8.70009 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 1235.8.70010 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 1235.8.70011 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 1235.8.70012 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 1235.8.42103 Boehringer Ingelheim Investigational Site
    Dolny Kubin, Slovakia
  • 1235.8.42106 Boehringer Ingelheim Investigational Site
    Kralovsky Chmlec, Slovakia
  • 1235.8.42104 Boehringer Ingelheim Investigational Site
    Liptovsky Mikulas, Slovakia
  • 1235.8.42102 Boehringer Ingelheim Investigational Site
    Povazska Bystrica, Slovakia
  • 1235.8.42105 Boehringer Ingelheim Investigational Site
    Presov, Slovakia
  • 1235.8.42101 Boehringer Ingelheim Investigational Site
    Trencin, Slovakia
  • 1235.8.42107 Boehringer Ingelheim Investigational Site
    Vrable, Slovakia
  • 1235.8.34008 Boehringer Ingelheim Investigational Site
    Badalona, Spain
  • 1235.8.34010 Boehringer Ingelheim Investigational Site
    Badalona, Spain
  • 1235.8.34009 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1235.8.34001 Boehringer Ingelheim Investigational Site
    Jerez de la Frontera (Cádiz), Spain
  • 1235.8.34006 Boehringer Ingelheim Investigational Site
    L'Hospitalet de Llobregat (Barcelona), Spain
  • 1235.8.34003 Boehringer Ingelheim Investigational Site
    Madrid, Spain
  • 1235.8.34004 Boehringer Ingelheim Investigational Site
    Madrid, Spain
  • 1235.8.34012 Boehringer Ingelheim Investigational Site
    Mataró, Spain
  • 1235.8.34002 Boehringer Ingelheim Investigational Site
    Oviedo, Spain
  • 1235.8.34005 Boehringer Ingelheim Investigational Site
    Santa Coloma de Gramanet, Spain
  • 1235.8.34011 Boehringer Ingelheim Investigational Site
    Santa Coloma de Gramanet, Spain
  • 1235.8.38010 Boehringer Ingelheim Investigational Site
    Dnepropetrovsk, Ukraine
  • 1235.8.38001 Boehringer Ingelheim Investigational Site
    Kharkov, Ukraine
  • 1235.8.38003 Boehringer Ingelheim Investigational Site
    Kharkov, Ukraine
  • 1235.8.38008 Boehringer Ingelheim Investigational Site
    Kharkov, Ukraine
  • 1235.8.38011 Boehringer Ingelheim Investigational Site
    Kharkov, Ukraine
  • 1235.8.38004 Boehringer Ingelheim Investigational Site
    Kiev, Ukraine
  • 1235.8.38006 Boehringer Ingelheim Investigational Site
    Kiev, Ukraine
  • 1235.8.38012 Boehringer Ingelheim Investigational Site
    Kiev, Ukraine
  • 1235.8.38013 Boehringer Ingelheim Investigational Site
    Kiev, Ukraine
  • 1235.8.38002 Boehringer Ingelheim Investigational Site
    Lvov, Ukraine
  • 1235.8.38005 Boehringer Ingelheim Investigational Site
    Odessa, Ukraine
  • 1235.8.38009 Boehringer Ingelheim Investigational Site
    Odessa, Ukraine
  • 1235.8.38007 Boehringer Ingelheim Investigational Site
    Zaporozhye, Ukraine
  • 1235.8.44010 Boehringer Ingelheim Investigational Site
    Bexhill on Sea, United Kingdom
  • 1235.8.44008 Boehringer Ingelheim Investigational Site
    Blackpool, United Kingdom
  • 1235.8.44016 Boehringer Ingelheim Investigational Site
    Blackpool, United Kingdom
  • 1235.8.44011 Boehringer Ingelheim Investigational Site
    Burbage, United Kingdom
  • 1235.8.44007 Boehringer Ingelheim Investigational Site
    Chestfield, Whitstable, United Kingdom
  • 1235.8.44005 Boehringer Ingelheim Investigational Site
    Chorley, United Kingdom
  • 1235.8.44002 Boehringer Ingelheim Investigational Site
    Edgbaston, Birmingham, United Kingdom
  • 1235.8.44009 Boehringer Ingelheim Investigational Site
    Ely, United Kingdom
  • 1235.8.44001 Boehringer Ingelheim Investigational Site
    Fowey, United Kingdom
  • 1235.8.44003 Boehringer Ingelheim Investigational Site
    Glasgow, United Kingdom
  • 1235.8.44012 Boehringer Ingelheim Investigational Site
    Penzance, United Kingdom
  • 1235.8.44013 Boehringer Ingelheim Investigational Site
    Plymouth, United Kingdom
  • 1235.8.44004 Boehringer Ingelheim Investigational Site
    Reading, United Kingdom
  • 1235.8.44015 Boehringer Ingelheim Investigational Site
    St. Austell, United Kingdom
  • 1235.8.44006 Boehringer Ingelheim Investigational Site
    Whitstable, United Kingdom
09

References and documents

Publications

  • Neldam S, Edwards C, Lang M, Jones R; TEAMSTA-5 and TEAMSTA-10 Investigators. Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. Curr Ther Res Clin Exp. 2012 Feb;73(1-2):65-84. doi: 10.1016/j.curtheres.2012.02.004. PubMed 24653513 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008 and a primary completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2008
First posted
Feb 26, 2008
Start
Mar 2008
Primary completionActual
Jun 2009
Results first posted
Mar 25, 2010
Last update
May 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00624052
First posted
Feb 26, 2008
Start date
Mar 2008
Primary completion
Jun 2009
Results posted
Mar 25, 2010
Last update
May 20, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion